A common hallmark of viral genome replication is a high mutation rate, which can aid in their ability to evade new treatments and acquire resistance to once-effective antiviral medications. Now, a new ...

Grouper iridoviruses, notably Singapore grouper iridovirus (SGIV), represent a major threat to global aquaculture owing to their ability to subvert host immunity and cause high mortality. Upon entry ...

An international team of researchers, led by the Leibniz Institute of Virology (LIV), have uncovered crucial details on how herpesviruses exit the cell nucleus without compromising the integrity of ...

Harvard Medical School researchers have uncovered crucial insights into how an emerging class of antiviral drugs works. The discovery sheds light on an important tool for fighting drug-resistant ...

This review article, published in LabMed Discovery by Prasanna Ganesan and Rengarajan Murugesan, explores the role of engineered vesicles—specifically extracellular vesicles (EVs) and synthetic ...

One of the main proteins that contributes to Alzheimer's disease is called phospho-tau (p-tau). When p-tau gets too many phosphate groups attached to it (a process called hyperphosphorylation), it ...

Cryo-EM images show drugs bound to herpes simplex virus protein at nearly atomic detail, while optical tweezer experiments show how the drug-bound protein behaves in real time. Harvard Medical School ...

A mechanism of antiviral immunity in bacteria has been characterized. A research team from Umeå University (Sweden) has uncovered a mechanism for how bacteria build up antiviral immunity against ...

The molecular pathways involved in antiviral defenses and counter-defenses in host-pathogen systems remain unclear. Researchers have used Neurospora crassa as a model organism to explore how RNA ...

NEWTOWN, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today ...

SHELTON, CT / ACCESSWIRE / September 26, 2024 / NanoViricides, Inc. (NYSE American.:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that ...